The treatment for antiplatelet drug<unk>  is not well defined. Detailed patient evaluation and correcting possible clinical causes and factors may be the initial therapeutic steps. Careful drug choose to reduce possible interactions, optimizing blood glucose and cholesterol levels are also beneficial.
Administration of higher doses of<unk>  is evaluated and currently not an actual therapeutic strategy for the lack of evidence demonstrating improvement in clinical outcomes. Increasing the dose of<unk>  has been suggested as a measure to overcome<unk> <unk>  but it is possible that increased doses of<unk>  may overcome<unk> <unk>  in vitro in an individual patient. Higher doses of<unk>  may also increase bleeding events.  
CAPRIE study (Clopidogrel versus<unk>  in Patients at Risk of Ischemic Events)
Although, whether clopidogrel therapy is superior to<unk>  in<unk>  resistant patients is currently unknown, CAPRIE study investigators reported significant superiority of clopidogrel monotherapy over<unk>  monotherapy. This beneficial effect was more frequently observed in high risk patients.
In fact,<unk> <unk>  is more frequent finding in high risk patients, such as diabetics and patients with diffuse atherosclerotic disease or acute coronary syndromes.  This group or patients also have increased risk of recurrent ischemic events     
ASCET trial<unk>  non-responsiveness and Clopidogrel Endpoint Trial)
ISAR-REACT study (Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action for Coronary Treatment) data suggest that in patients at low to intermediate risk who undergo elective<unk>  after pretreatment with a high loading dose of clopidogrel, the use of a GP IIb/IIIa inhibitor, although more potent, is associated with no clinically measurable benefit within the first 30 days. In contrast, high-risk patients should receive triple antiplatelet therapy.
A low to medium risk patients study suggests that<unk>  and clopidogrel may be insufficient in<unk>  non responsive patients and resulted in quite similar results of ISAR-REACT. 
Both study results indicate that there is a gap between applied medication and requirements for optimal antiplatelet treatment.
Most interventional cardiologists give<unk> , clopidogrel, and heparin alone before<unk> , however, up to 25% of these patients are<unk>  non responsive.
RESISTOR trial (Research Evaluation to Study Individuals who Show Thromboxane Or P2Y12 Receptor<unk>
PCI in The Patient With Resistance to Aspirin
Appropriate use criteria for revascularization
PCI in the patient at risk of bleeding
PCI in the patient with in stent restenosis
Coronary artery bypass surgery heart team approach to revascularization decisions
List of Class III recommendations in guidelines for cardiovascular medicine
Antiplatelet therapy to support PCI
Predictors of coronary stent thrombosis